EP3505161A4 - Sublingual pharmaceutical composition of edaravone and (+)-2-borneol - Google Patents
Sublingual pharmaceutical composition of edaravone and (+)-2-borneol Download PDFInfo
- Publication number
- EP3505161A4 EP3505161A4 EP17845291.8A EP17845291A EP3505161A4 EP 3505161 A4 EP3505161 A4 EP 3505161A4 EP 17845291 A EP17845291 A EP 17845291A EP 3505161 A4 EP3505161 A4 EP 3505161A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- edaravone
- borneol
- pharmaceutical composition
- sublingual pharmaceutical
- sublingual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical group O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title 1
- 229950009041 edaravone Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610761890.7A CN107773545A (en) | 2016-08-29 | 2016-08-29 | The sublingual pharmaceutical composition of Edaravone and (+) 2 baras camphor |
PCT/CN2017/098620 WO2018040989A1 (en) | 2016-08-29 | 2017-08-23 | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3505161A1 EP3505161A1 (en) | 2019-07-03 |
EP3505161A4 true EP3505161A4 (en) | 2020-04-22 |
EP3505161B1 EP3505161B1 (en) | 2021-05-12 |
Family
ID=61300111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17845291.8A Active EP3505161B1 (en) | 2016-08-29 | 2017-08-23 | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol |
Country Status (10)
Country | Link |
---|---|
US (1) | US11135199B2 (en) |
EP (1) | EP3505161B1 (en) |
JP (1) | JP6751475B2 (en) |
KR (1) | KR102216381B1 (en) |
CN (2) | CN107773545A (en) |
AU (1) | AU2017317950B2 (en) |
CA (1) | CA3037089C (en) |
RU (1) | RU2720204C1 (en) |
WO (1) | WO2018040989A1 (en) |
ZA (1) | ZA201901866B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109431966B (en) * | 2018-04-27 | 2020-09-22 | 首都医科大学附属北京天坛医院 | Edaravone pharmaceutical composition |
US20220409588A1 (en) * | 2019-07-18 | 2022-12-29 | Bdr Pharmaceuticals International Private Limited | Oral formulations of edaravone and method of manufacturing thereof |
WO2022007831A1 (en) * | 2020-07-08 | 2022-01-13 | 先声药业有限公司 | Medical use of composition |
US20230364059A1 (en) * | 2020-08-17 | 2023-11-16 | Simcere Pharmaceutical Co., Ltd. | Stable pharmaceutical composition |
CN114099500B (en) * | 2020-08-26 | 2023-09-22 | 上海云晟研新生物科技有限公司 | Edaravone sustained-release pharmaceutical composition, preparation method and application |
CN112426433B (en) * | 2020-12-23 | 2022-08-05 | 湖南中医药大学 | Borneol angelica polysaccharide liposome for resisting cerebral ischemia inflammatory reaction and preparation method thereof |
AU2022234307A1 (en) * | 2021-03-10 | 2023-10-19 | Giri, Rajan Shobhanath | Compounds for treating conditions related to oxidative stress |
CA3236969A1 (en) * | 2021-11-08 | 2023-05-11 | Zhengping Zhang | Application of composition containing edaravone and dexborneol in improving or treating cognitive impairment |
WO2024038471A1 (en) * | 2022-08-18 | 2024-02-22 | Bdr Pharmaceuticals International Private Limited | Oral formulations of edaravone and improved method of manufacturing thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3775960D1 (en) | 1986-03-10 | 1992-02-27 | Burghart Kurt | PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF. |
IE60601B1 (en) | 1986-08-27 | 1994-07-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for the treatment of disorders associated with cerebral ischemia |
KR950010727B1 (en) * | 1993-06-10 | 1995-09-22 | 엘지전선주식회사 | Terminal for power cable |
CN1263472C (en) | 2002-11-29 | 2006-07-12 | 张永 | Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease |
CN1739588A (en) * | 2005-09-06 | 2006-03-01 | 王衡新 | Chinese medicine prepn for treating cardiac vascular diseases and its prepn |
CN101524352A (en) | 2008-03-04 | 2009-09-09 | 江苏先声药物研究有限公司 | Composition containing 3-methyl-1-phenyl-2-pyrazoline-5-ketone |
CN102485223A (en) | 2010-12-01 | 2012-06-06 | 江苏先声药物研究有限公司 | Pharmaceutical composition and application thereof to preparation of medicament for treating cerebrovascular disease |
CN102579432B (en) * | 2011-01-12 | 2016-05-11 | 江苏先声药物研究有限公司 | The application of 3-methyl-1-phenyl-2-pyrazolin-5-one and 2-borneol composition |
CN106794146A (en) | 2014-03-04 | 2017-05-31 | 伊斯特盖特医药公司 | Pharmaceutical composition for transmucosal delivering and the method for treating diabetes in the subject for needing |
-
2016
- 2016-08-29 CN CN201610761890.7A patent/CN107773545A/en active Pending
-
2017
- 2017-08-23 AU AU2017317950A patent/AU2017317950B2/en active Active
- 2017-08-23 JP JP2019530537A patent/JP6751475B2/en active Active
- 2017-08-23 WO PCT/CN2017/098620 patent/WO2018040989A1/en active Application Filing
- 2017-08-23 CN CN201780048512.7A patent/CN109906077B/en active Active
- 2017-08-23 EP EP17845291.8A patent/EP3505161B1/en active Active
- 2017-08-23 KR KR1020197005273A patent/KR102216381B1/en active IP Right Grant
- 2017-08-23 US US16/326,470 patent/US11135199B2/en active Active
- 2017-08-23 RU RU2019108605A patent/RU2720204C1/en active
- 2017-08-23 CA CA3037089A patent/CA3037089C/en active Active
-
2019
- 2019-03-26 ZA ZA2019/01866A patent/ZA201901866B/en unknown
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO2018040989A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3505161A1 (en) | 2019-07-03 |
KR102216381B1 (en) | 2021-02-18 |
CA3037089A1 (en) | 2018-03-08 |
AU2017317950B2 (en) | 2019-09-19 |
CN109906077A (en) | 2019-06-18 |
US20200297697A1 (en) | 2020-09-24 |
CA3037089C (en) | 2021-02-16 |
AU2017317950A1 (en) | 2019-02-21 |
JP6751475B2 (en) | 2020-09-02 |
RU2720204C1 (en) | 2020-04-27 |
ZA201901866B (en) | 2020-10-28 |
KR20190031316A (en) | 2019-03-25 |
CN109906077B (en) | 2020-02-07 |
US11135199B2 (en) | 2021-10-05 |
JP2019524893A (en) | 2019-09-05 |
WO2018040989A1 (en) | 2018-03-08 |
EP3505161B1 (en) | 2021-05-12 |
CN107773545A (en) | 2018-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3505161A4 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
EP3595653A4 (en) | Compositions of plinabulin and use thereof | |
EP3303413A4 (en) | Processes for preparation of sugammadex and intermediates thereof | |
EP3209681A4 (en) | Pharmaceutical compositions comprising peptide variants and methods of use thereof | |
EP3509581A4 (en) | Formulations of (r | |
EP3102555A4 (en) | Compositions of compounds and uses thereof | |
EP3435956A4 (en) | Photo-stabilized compositions and methods of use | |
EP3157929A4 (en) | Pyrazole compounds as modulators of fshr and uses thereof | |
EP3500286A4 (en) | N-carboxyanhydride-based-scale synthesis of elamipretide | |
EP3349743A4 (en) | Methods and compositions of inhibiting dcn1-ubc12 interaction | |
EP3411413A4 (en) | Synthesis and composition of rapafucin libraries | |
EP3323413A4 (en) | Pharmaceutical composition containing celecoxib and tramadol | |
EP3490569A4 (en) | Topical compositions and methods of using thereof | |
EP3288379A4 (en) | Peptide compositions and methods of use | |
EP3512521A4 (en) | Extended release pharmaceutical composition of clozapine | |
EP3310794A4 (en) | Synthesis and application of microbubble-forming compounds | |
EP3506895A4 (en) | Magnesium biotinate compositions and methods of use | |
EP3302412A4 (en) | Once daily oral pharmaceutical composition of isotretinoin | |
EP3277701A4 (en) | Synthesis of desosamines | |
EP3510120A4 (en) | Carbonate compositions and methods of use thereof | |
EP3524250A4 (en) | Pharmaceutical composition | |
EP3367998A4 (en) | Novel method of use and compositions | |
EP3554547A4 (en) | Pharmaceutical composition containing celecoxib | |
EP3302438A4 (en) | Oral pharmaceutical composition of isotretinoin | |
EP3503885A4 (en) | Pharmaceutical composition and methods of uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190220 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/34 20170101ALI20200312BHEP Ipc: A61K 47/26 20060101ALI20200312BHEP Ipc: A61K 47/40 20060101ALI20200312BHEP Ipc: A61P 9/10 20060101ALI20200312BHEP Ipc: A61K 9/20 20060101AFI20200312BHEP Ipc: A61K 47/12 20060101ALI20200312BHEP Ipc: A61K 31/4152 20060101ALI20200312BHEP Ipc: A61K 31/045 20060101ALI20200312BHEP Ipc: A61K 9/00 20060101ALI20200312BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200320 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40009745 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20201204 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEURODAWN PHARMACEUTICAL CO., LTD. Owner name: SIMCERE PHARMACEUTICAL CO. LTD. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: ISLER AND PEDRAZZINI AG, CH |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017038629 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1391701 Country of ref document: AT Kind code of ref document: T Effective date: 20210615 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1391701 Country of ref document: AT Kind code of ref document: T Effective date: 20210512 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210512 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210812 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210912 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210813 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210812 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017038629 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |
|
26N | No opposition filed |
Effective date: 20220215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210912 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210823 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170823 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230828 Year of fee payment: 7 Ref country code: GB Payment date: 20230920 Year of fee payment: 7 Ref country code: CH Payment date: 20230902 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230831 Year of fee payment: 7 Ref country code: DE Payment date: 20230911 Year of fee payment: 7 Ref country code: BE Payment date: 20230822 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210512 |